Dear Colleagues,

As we take a moment to celebrate the holiday season and the arrival of a New Year with our friends, family and loved ones, let us also take a moment to recognize our successes in 2023.

I am awed by your dedication to our mission, helping to find better treatment strategies for our patients, which is reflected in the accomplishments we have achieved. Thank you, GOG-F Sites, for your efforts, commitment, and contributions from our incredible teams, institutions, and practices. I am humbled to work with an amazing team of physician leaders, and an incredible staff that make the magic happen on a daily basis.

In the coming year, we will continue our focus on transforming the standard of care for all patients with gynecologic cancer. It is our goal to ensure that our clinical trial enrollment reflects our disease-state populations by proportionately including racial and ethnic minorities in our trials. It is our collective passion to expediently enroll existing GOG-F trials and develop novel studies in the upcoming year. We have the privilege to work in health care, and the health and wellbeing of ourselves and our community are important priorities that can suffer with everyone working days, nights, weekends, and holidays. Thus, I want to extend a heartfelt thank you to all of you for your tireless efforts on behalf of our patients.

But with these continuous demands, it is important to disconnect and take time to reenergize, relax, and recharge. Self-care is easy to neglect as we devote our energies to serving others—patients, colleagues, friends, and families—but it is key to our physical and mental health. Please make yourself a priority during this holiday season.
I hope that you share my immense gratitude for the opportunity that we have to work, laugh, empathize, and support one another. Together, we will start 2024 stronger than ever.

Together, our strength will continue to positively impact patients through the prevention and treatment of gynecologic cancers. On behalf of the GOG-F, I wish you a safe and healthy holiday season and a most prosperous New Year.

Happiest of holidays to each of you!

With warmest regards,
Tom

---

**GOG PARTNERS INVESTIGATOR INITIATED TRIAL APPLICATION NOW OPEN**

In support of our dedication to transforming the standard of care in gynecologic oncology, the GOG Foundation, Inc. Investigator Initiated Trial (IIT) program supports studies with scientific merit that are independent of academic, government or industry sponsored trials. These trials are designed to have a direct impact on patients by assessing available treatments and generating data applicable to the local population at both academic and community-based sites through the GOG Partners Program. GOG physician leadership provides mentorship for the next generation of investigators leading these IITs.

GOG is currently accepting new IIT Letter of Intent (LOI) applications until **January 18, 2024**. Applications should be submitted electronically using the IIT LOI form on the GOG website.

All applications will be reviewed jointly by the GOG Partners IIT Committee based on:

- Scientific Relevance
- Practice-Changing Potential
- Study Design
- Study Feasibility
- Use of Standard of Care Assessments

Proposed studies must be IND Exempt to be considered by GOG. Applicants must be on staff of a GOG network site in good standing.

Please contact GOGPartners@gog.org with any questions.

---

**SPECIAL RECOGNITION**

Premal Thaker, MD named the inaugural David & Lynn Mutch Distinguished Professor of Obstetrics
Premal H. Thaker, MD, MS, an accomplished clinician investigator and Director of Gynecologic Oncology Clinical Trials, has been named the David & Lynn Mutch Distinguished Professor of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.

“We are truly fortunate to have Dr. Thaker as a valued member of our faculty. Her outstanding contributions to patient care, clinical and translational research, and training the next generation of students, residents and fellows, make her the ideal recipient of this tremendous honor,” said Dineo Khabele, MD, Chair of the Department of OB/GYN.

“Since I was recruited by Dr. Mutch after completing my fellowship at M. D. Anderson Cancer Center, I am very humbled, honored, and delighted to be the inaugural David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology,” Dr. Thaker stated. “I would like to thank the Berges Family Foundation for their support in honoring Dr. Mutch who is the epitome of the tripartite mission: research, education, and patient care. I am privileged that I have been selected to continue his legacy and vision to strengthen our ability to advance new treatments with clinical trials, to educate the next generation of leaders, and to treat gynecologic oncology patients with compassion and grace”. Premal Thaker, MD

Click here to read the full article.
IN THE NEWS

THE LANCET GOG-3030 (BEATcc) PUBLICATION

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

The GOG-0240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Click here to read the full publication.

THE NEW ENGLAND JOURNAL OF MEDICINE GOG-3045 (MIRASOL) PUBLICATION

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States.

Click here to read the full publication.

---

THE WHITE HOUSE FACT SHEET

**President Joe Biden to Announce First-Ever White House Initiative on Women’s Health Research, An Effort Led by First Lady Jill Biden and the White House Gender Policy Council**

The new initiative will fundamentally change how we approach and fund women’s health research.

Despite making up more than half of the population, women have been understudied and underrepresented in health research for far too long. Research on women's health is drastically underfunded, leading to significant research gaps, with serious consequences for the health of women across the country. This lack of investment limits our understanding of conditions that are specific to women, predominantly affect women, or affect women differently. In order to give women and their health care providers the tools and information that they need to more effectively prevent, diagnose, and treat these conditions – from rheumatoid arthritis to menopause to Alzheimer’s disease to cardiovascular disease to endometriosis – our nation must fundamentally change how we approach and fund women’s health research.

Click here to read the full announcement.

---

GYNECOLOGIC ONCOLOGY GOG-3032 (MOONSTONE) PUBLICATION

**Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study**

This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed death-1 inhibitor, combined with niraparib, a poly (ADP-ribose) polymerase inhibitor, in patients with BRCA wild type (BRCAwt) recurrent platinum-resistant ovarian cancer (PROC) who had previously received bevacizumab treatment.

Click here to read the full publication.

---

FOX NEWS CHANNEL innovaTV301 | ENGOT-cx12 GOG-3057 ARTICLE

**A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second -or Third-Line recurrent or Metastatic Cervical Cancer**
"To have an overall survival advantage in this disease is extremely, extremely rare. It changes the second-line standard of care for this disease. Now, all patients who recur after first-line therapy should be considered for this therapy. So it's a game-changer." Brian Slomovitz, MD

Click here to read the full article.

---

JOURNAL OF CLINICAL ONCOLOGY ENGOT-cx8| GOG-3024 innovaTV205 PUBLICATION

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).

Click here to read full publication.

---

LOW-GRADE SEROUS OVARIAN CANCER: EXPERT CONSENSUS REPORT ON THE STATE OF THE SCIENCE VIDEO PODCAST

Click here to view the full video podcast.

To learn more about low-grade serous ovarian cancer, click here to view the panel’s Low-grade serous ovarian cancer: expert consensus report on the state of the science paper published in the International Journal of Gynecologic Cancer.

---

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 22 clinical trials

- 15 Ovary
GOG-3031 (RUBY) PRESS RELEASE

Jemperli (dostarlimab-gxly) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer

December 2, 2023 – GSK plc (LSE/NYSE: GSK) today announced positive headline results from the planned interim analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. The trial met its primary endpoint of investigator-assessed progression-free survival (PFS). It showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.

While the overall survival (OS) data were immature at the time of this analysis, a favorable trend was observed in the overall population, including both the dMMR/MSI-H and MMRp/MSS subgroups.

The safety and tolerability profile of dostarlimab-gxly in the RUBY phase III trial was consistent with clinical trials of similar regimens. The most common treatment-emergent adverse events in patients receiving dostarlimab-gxly plus chemotherapy were nausea, alopecia, fatigue, peripheral neuropathy, anemia, arthralgia, constipation and diarrhea.

Click here to view the full press release.

GOG-3020 (ATHENA) PRESS RELEASE

European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
Vienna, Austria, November 20, 2023 – pharma& GmbH (pharma&) announced today that the European Commission (EC) has granted marketing authorization for a Type II variation for Rubraca® (rucaparib) as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.

Rucaparib was previously approved as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy.

Click here to view the full press release.

---

innovaTV 301 | ENGOT cx12 | GOG-3057
PRESS RELEASE

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

October 22, 2023: Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced results today from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy (HR: 0.70, 95% CI: 0.54-0.89, p=0.00381). Data were presented during the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress 2023.

“Patients with cervical cancer have few treatment options once their cancer comes back or spreads after initial treatment,” said Ignace B. Vergote, M.D., Ph.D., co-founder of European Network of Gynaecological Oncological Trial groups (ENGOT), and lead investigator on the innovaTV 301/ENGOT cx-12/GOG 3057 clinical trial. “The positive data, seen in a representative patient population of recurrent or metastatic cervical cancer, demonstrate the potential for TIVDAK to reshape clinical practice and provide hope for patients who need a new treatment option.”

Click here to view the full press release.

---

GOG-3041 (DUO-E) | ENGOT-EN10 PRESS RELEASE

Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

October 21, 2023: Positive results from the primary analysis of the DUO-E Phase III trial showed that Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib), both demonstrated a statistically significant
and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer.

Shannon N. Westin, Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and principal investigator of the trial, said, “These findings showcase, for the first time, the potential of combining immunotherapy with a PARP inhibitor to deliver significant clinical improvements for these patients. These DUO-E data may offer oncologists novel avenues to enhance outcomes for endometrial cancer patients.”

Click here to view the full press release.

ENGOT-cx11| GOG-3047 (KEYNOTE A18) PRESS RELEASE

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

September 20, 2023: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer. The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone. If approved, this would be Merck’s third approved indication in cervical cancer and first in an earlier stage of the disease. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2024.

“The standard of care for patients with locally advanced cervical cancer has not changed in more than two decades, and the majority of patients will experience recurrence or progression of their disease,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “If approved, KEYTRUDA will be the first immunotherapy available for patients with newly diagnosed high-risk locally advanced cervical cancer. We are committed to working closely with the FDA to bring KEYTRUDA to these patients who are in need of additional treatment options.”

Click here to view the full press release.
Click here to view the full video podcast and learn more about this clinical trial in recurrent low-grade serous ovarian cancer.

UPCOMING INDUSTRY MEETINGS

NRG 2024 WINTER MEETING

The NRG 2024 Winter Meeting will be held February 15 - 17, 2024 in Orlando, Florida at the World Center Marriott.

Click here to visit the NRG 2024 Winter Meeting resource pages that will provide up-to-date registration and hotel information, agendas, and session recordings. Please visit the Help page if you have unanswered questions or need support.

SGO 2024 WINTER MEETING

The SGO Winter Meeting will be held January 25 - 27, 2024 at the Everline Resort & Spa in Olympic Valley, California.

Gynecologic oncologists, radiation oncologists, medical oncologists, obstetricians and gynecologists, and allied health professionals involved in the care of patients who have gynecologic cancers are encouraged to attend the SGO Winter Meeting.

Click here to register to attend.

ESGO 2024 CONGRESS

The ESGO 2024 Congress will be held March 7 - 10, 2024 in Barcelona, Spain.

ESGO 2024 will be a celebration of discovery and late-breaking research, new guidelines, practical demonstrations, and
exclusive live surgery transmissions from hospitals you don't want to miss.

The 25th Congress of the European Society of Gynaecological Oncology will bring together over 2,000 attendees from around the world for a four-day gathering of learning, networking, and sharing the latest developments in the field of Gynaecological Cancers—all with the goal of enhancing your knowledge, accelerating your skills and advancing the field.

Click here for more information.

**2024 SGO ANNUAL MEETING ON WOMEN'S CANCER**

The 2024 SGO Annual Meeting on Women's Cancer will be held **March 16 - 18, 2024 in San Diego, California.**

Since 1969, gynecologic oncology professionals have convened at the Society of Gynecologic Oncology (SGO)'s Annual Meeting on Women's Cancer to discuss the latest science in the field, receive educational programming, and to network.

Members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, surgery, and palliative care attend the SGO Annual Meeting. Gynecologic oncologists make up a large population of the attendees, along with medical oncologists, pathologists, radiation oncologists, hematologists, surgical oncologists, obstetrician/gynecologists, nurses, physician assistants, fellows in training, residents, and pharmacists.

Click here for more information.

**ON DEMAND EDUCATION**

**OVARIAN CANCER ONLINE SYMPOSIUM**

Join this three-part, online symposium for impactful ovarian cancer information, education and support. The sessions are personalized for patients, caregivers and other advocates and offered at no cost to participants.

- Symposium Intro & Ovarian Cancer Overview
- Platinum-Sensitive and Platinum-Resistant Recurrence
- Understanding Clinical Trials and The OC Roadmap

Click here to register to access the Ovarian Cancer Online Symposium video recordings.

The Clearity Foundation and GOG Partners are grateful for our commercial supporters for Independent Medical Education associated with this podcast series: **Novocure, Verastem, Immunogen, Alkermes, R-Pharm US, GSK.**
**THE GOG HIGHLIGHT REEL - FALL 2023**

**Access to Symposium Recording**
Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the GOG Highlight Reel – Fall 2023 recording.

**Access to Symposium Presentations**
Please [click here](#) to access the individual presentation files on the GOG website.

---

**2023 IGCS ANNUAL GLOBAL MEETING**

You may access IGCS 2023 On-Demand by logging into [IGCS Education360 Learning Portal](#) with your IGCS account login information, which is same information you used to register for the meeting.

**On-Demand is available until February 5, 2024.**

If you are unsure of your IGCS account login information, please contact [igcs@igcs.org](mailto:igcs@igcs.org).

Once you are logged into Education360 Learning Portal, select “My Courses” on the left panel.

From the list of your courses find “IGCS 2023 Annual Global Meeting - On-Demand”.

Within this course, you will find recordings, abstracts, ePosters, and surgical films.

Don't miss out on the following Industry Supported Symposia that were presented at the 2023 IGCS Annual Global Meeting!
PHILANTHROPY

MOVE 4 HER CAMPAIGN

Discover the power of unity as Move4Her brings together patients, survivors, caregivers, healthcare professionals, and organizations, encouraging everyone to stay active and motivated to reach their fundraising goals through the end of 2023.

All it takes is a commitment to FIVE minutes of daily movement! Join the movement as an individual fundraiser, donate to support a friend or family member, start your own fundraising team, or host your own unique
fundraising event. No matter your approach, we are here to support you every step of the way on your fundraising journey.

Click here to Register now to become a Move4Her fundraiser and start raising funds as an individual or as part of a team.

NEW HORIZONS GYNECOLOGIC CANCER RESEARCH FUND

The New Horizons Gynecologic Cancer Research Fund is the philanthropic arm for The GOG Foundation, Inc. Donations allow the GOG to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs.

Donations from individuals, corporations, and foundations directly fund the GOG educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:
- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

Support Our Mission

HOW CAN WE HELP?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.

LET'S GET SOCIAL